MX2014002343A - Inhibidores de parp. - Google Patents

Inhibidores de parp.

Info

Publication number
MX2014002343A
MX2014002343A MX2014002343A MX2014002343A MX2014002343A MX 2014002343 A MX2014002343 A MX 2014002343A MX 2014002343 A MX2014002343 A MX 2014002343A MX 2014002343 A MX2014002343 A MX 2014002343A MX 2014002343 A MX2014002343 A MX 2014002343A
Authority
MX
Mexico
Prior art keywords
parp
compounds
parp inhibitors
inhibitors
formula
Prior art date
Application number
MX2014002343A
Other languages
English (en)
Spanish (es)
Inventor
Nancy-Ellen Haynes
Nathan Robert Scott
Nicholas John Silvester Huby
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014002343A publication Critical patent/MX2014002343A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2014002343A 2011-09-01 2012-08-29 Inhibidores de parp. MX2014002343A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161529942P 2011-09-01 2011-09-01
PCT/EP2012/066721 WO2013030205A1 (en) 2011-09-01 2012-08-29 Parp inhibitors

Publications (1)

Publication Number Publication Date
MX2014002343A true MX2014002343A (es) 2014-04-30

Family

ID=46796563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002343A MX2014002343A (es) 2011-09-01 2012-08-29 Inhibidores de parp.

Country Status (9)

Country Link
EP (1) EP2758370A1 (ko)
JP (1) JP2014531416A (ko)
KR (1) KR20140062096A (ko)
CN (1) CN103906730A (ko)
BR (1) BR112014005011A2 (ko)
CA (1) CA2846429A1 (ko)
MX (1) MX2014002343A (ko)
RU (1) RU2014110624A (ko)
WO (1) WO2013030205A1 (ko)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5441864A (en) * 1977-09-02 1979-04-03 Sankyo Co Ltd Beta-lactam homolog and its preparation
US7642277B2 (en) * 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
JP2009539963A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Parp阻害剤
WO2010139966A1 (en) * 2009-06-05 2010-12-09 Oslo University Hospital Hf Azole derivatives as wtn pathway inhibitors

Also Published As

Publication number Publication date
EP2758370A1 (en) 2014-07-30
BR112014005011A2 (pt) 2017-05-30
CA2846429A1 (en) 2013-03-07
KR20140062096A (ko) 2014-05-22
RU2014110624A (ru) 2015-10-10
CN103906730A (zh) 2014-07-02
JP2014531416A (ja) 2014-11-27
WO2013030205A1 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
IN2012DN03883A (ko)
JO3131B1 (ar) مركبات كيميائية
IN2014KN02601A (ko)
PH12014502513A1 (en) Nampt inhibitors
SG190819A1 (en) Nampt and rock inhibitors
MX2014013752A (es) Inhibidores de nampt.
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
MX348311B (es) Inhibidores nampt.
MX2014007840A (es) Dihidrodiazpinocarbazolonas tetra o penta-cicliclas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
MX348024B (es) Compuestos de adamantilo.
IN2015DN01151A (ko)
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
PH12017500595B1 (en) Aldosterone synthase inhibitors
PH12015502032A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
IN2012DN03846A (ko)
MX2014000374A (es) Compuesto de aminometil quinolona.
MX2014003883A (es) Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y transtornos relacionados.